Alumis logo

Alumis

ALMS | NASDAQ
Chart Builder DCF Calculator
$5.14
-$0.46 (-8.21%)
At close: Nov 16, 2026, 4:00 PM ET
$5.05
-$0.09 (-1.75%)
After-hours: Nov 16, 2026, 7:57 PM ET
-8.21%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
52.2
+7.0 pts
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #234/1021 (Top 23%)

Key Statistics

Market Data

Market Cap $665.3M
1D Range
5.00 5.80
52W Range
5.00 30.30

Valuation (TTM)

PE -1.48
PB 1.76
EV/EBITDA -0.63

Valuation (NTM)

Forward PE N/A
Forward PEG -0.11
Price Target $29.00
Loading financial charts...

Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 ...

Sector Healthcare
Industry Biotechnology
Employees 237
IPO Date Jun 28, 2024
Fiscal Year January - December

Latest News

Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alumis to Participate in Upcoming September Investor Conferences

2 months ago · globenewswire.com

Alumis to Participate in Upcoming September Investor Conferences
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside

3 months ago · seekingalpha.com

Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript

3 months ago · seekingalpha.com

Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise

3 months ago · marketbeat.com

Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
Alumis eyes late-stage lupus study despite trial miss

3 months ago · reuters.com

Alumis eyes late-stage lupus study despite trial miss
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

3 months ago · globenewswire.com

Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

3 months ago · globenewswire.com

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

3 months ago · zacks.com

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates

3 months ago · benzinga.com

Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates

Earnings

Latest Earnings
Nov 12, 2026
EPS
-$0.73
Beat +3.69%
REV
$1.91M
Beat +0.37%
Next Earnings
Mar 18, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$28.00
Upside
+444.75%
Buy (6)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.